Inventiva SA’s stock (IVA) soared over 30% on Monday after the company announced securing significant financing for its NASH drug, lanifibranor. This funding will fuel the completion of the Phase 3 NATiV3 MASH trial and potential marketing approval, boosting investor confidence.
Viking Therapeutics (“VKTX”) reported financial results for Q1 2024, showing a wider net loss despite beating estimates on the bottom line. The company’s net loss widened to $27.4 million, compared to $19.5 million a year ago. Basic and diluted net loss per share was -$0.26, a slight increase from the previous quarter’s -$0.25. Viking’s total assets increased significantly to $967.5 million as of March 31, up from $368.5 million on December 31, 2023. The company plans to release data from the secondary and exploratory objectives of its VOYAGE study on the effectiveness of VK2809 for non-alcoholic steatohepatitis (NASH) later this quarter.
Hepion Pharmaceuticals Inc. (HEPA) has announced the wind-down of its ASCEND-NASH Trial, a Phase 2b study evaluating the safety and efficacy of rencofilstat for the treatment of non-alcoholic steatohepatitis (NASH). The decision was made due to resource constraints and the low probability of generating sufficient efficacy data to support a registrational trial. Approximately 80 subjects have completed their Day 365 visits and will be evaluated for safety and efficacy, while an additional 40 subjects will provide safety data. There were no safety concerns observed for rencofilstat in the trial.
